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Abstract 
We describe the placement of an endovascular stent-graft in a patient with mycotic aneurysm of the descending 
thoracic aorta caused by Salmonella. Endovascular grafting combined with antibiotic therapy in thoracic mycotic 
aneurysms might represent an alternative to conventional surgery in patients with high operative risk. 
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1. Introduction 
Aortic mycotic aneurysm is a rare pathology with a high mortality rate. Conventional treatment is surgical 
intervention followed by long-term antibiotic therapy. In patients with high operative risk, surgery may become 
prohibitive. Endoluminally placed stent-graft as an alternative to open surgery has gained interest to treat 
thoracic aortic aneurysms. 
2.  Case report 
A 84-year-old female was admitted to the emergency room for dyspnea, haemoptoic expectoration, chills and 
sweating. The patient reported backache for a week and episodes of diarrhea. Clinical examination showed blood 
pressure of 90/50 mmHg, regular pulse rate of 56/min and rectal body temperature of 38.4°C. Relevant 
laboratory results showed a leukocytosis of 23.19/mm3 (normal range: 4.3-11.9) and a C-reactive protein of 249 
mg/l (normal range: 0-6). Chest radiograph demonstrated a retrocardiac opacity suggestive of aneurysm of the 
descending thoracic aorta. Spiral contrast enhanced CT confirmed an aneurysm of the descending thoracic aorta, 
13 cm in length with a maximum diameter of 8 cm, compressing moderately the heart chambers and reducing to 
80% the lumen of the lower lobe bronchus (Fig. 1). Diameter of normal aorta was 29 mm. Sputum and blood 
cultures were positive for Salmonella enteritidis. An aorto-bronchial fistula could be suspected but bronchoscopy 
was not realized due to an emergency state. Intravenous therapy with new quinolones was started. Age and 
debilitated condition of the patient precluded thoracic surgery. As an alternative, endovascular stentgrafting was 
performed by right femoral arteriotomy five days after admission. Peroperative arteriography showed an 
aneurysm with an adequate landing zone for stent graft, anchored distal to the ostium of the left subclavian artery 
(Fig. 2). Three stentgrafts (Talent®, Medtronic, Minneapolis, USA) with an expanded diameter of 38 mm and a 
length of 114 mm were placed in an overlapping position, from the ostium of the left subclavian artery to 15 mm 
proximal to the origin of the celiac artery. Antibiotic therapy was stopped after 6 weeks. CT at 3 months follow-
up showed complete exclusion of the thrombosed aneurysmal sac without visible endoleak. There  was  no  
postoperative  complication.  Laboratory results showed a white blood cell count and a C-reactive protein in the 
normal range. The patient was alive and well at 6-months follow-up. Haemoptoic expectoration did not recur 
after the intervention. 
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Fig. 1. Multisclice CT (MSCT) obtained after i.v. contrast injection shows in a coronal reformatted plane (a) and in 3D In 
Space view (Siemens) (b) the mycotic aneurysm of the descending thoracic aorta and extensive peripheral thrombosis of the 
aneurysmal sac [asterisk]. Multiplanar reconstruction (MPR) images show proximal extension of the thrombosed aneurysm 
to the aortic isthmus and distal extension to the abdominal aorta [arrow-head]. 
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Fig. 2. (a) Multisclice CT (MSCT) obtained one month after endoluminal stentgrafting shows exclusion of the mycotic 
aneurysm [asterisk] without endoleak. (b) Oblique multiplanar reconstruction (MPR) view in maximum intensity projection 
(MIP) shows correct position of the aortic stentgraft deployed from distal to the left subclavian artery to the distal thoracic 
aorta. 
 
 
3. Discussion 
Mycotic aneurysms are aneurysms caused by arterial infection while aneurysms that have become secondarily 
infected are infected aneurysms. Most common pathogens involved in infected aorta are Salmonella, 
Staphylococcus and Streptococcus, responsible of microbial arthritis which results in aneurysm formation. There 
is a predilection for atherosclerotic lesions, aneurysms, vascular prosthetic reconstructions and sites of 
penetrating arterial trauma. Salmonella species are the most frequent pathogens found in mycotic aneurysm 
involving the aorta, accountig for 35% of cases [1-2]. Involvement of the thoracic aorta is rare, and few cases 
have been reported previously [1-4]. 
Clinical symptoms and findings of vascular infection are varied and often subtle. Chest X-ray may show saccular 
widening of the aorta. CT is a major diagnostic modality to demonstrate mycotic aortic aneurysm [5]. Magnetic 
resonance imaging gives similar diagnostic results to CT, without ionizing radiation and less nephrotoxic effects 
induced by MR contrast agents, but availability may be more limited. Pet-scan may suggest an infectious 
etiology of aneurysmal lesions, but does not identify the microbial etiology. 
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Untreated mycotic thoracic aneurysm caused by Salmonella is invariably fatal [1-3]. Standard treatment 
combines surgical correction and antibiotic therapy. Surgical options are aortic exclusion and extra-anatomic 
bypass or surgical placement of in situ graft [1-3,6]. 
Extra-anatomic bypass grafting may be difficult or technically impossible because of location of the aneurysm. 
For these reasons, in situ graft placement is recommended with resection of the aneurysm and insertion on end-
to-end tube graft, either woven polyester or preserved human cadaveric allograft. In situ insertion of an aortic 
conduit allograft might reduce late post-operative infection and improve survival in high-risk patients [6]. Hsu et 
al. suggest that surgical treatment has to be considered after 4-6 weeks, in patient who have a good response to 
antibiotic therapy. Early surgical intervention should be performed only for uncontrolled infection or risk of 
rupture, as in our case [1]. In all cases, a prolonged antibiotic therapy is necessary ranging from 6 weeks to life 
time. Ampicillin, chloramphenicol and thrimethoprim-sulfamethoxazole have been the standard treatments of 
systemic salmonella infection. Third generation cephalosporins and new quinolones have been documented to be 
more effective against Salmonella species [1 -3]. 
In patients with high operative risk, such as coronary arteriopathy, emphysema, orpoor general condition, 
surgical treatment may become prohibitive. Repair of thoracic aortic aneurysms by endoluminal stentgrafting is 
an emerging alternative to open surgical intervention, including treatment of mycotic aneurysm [4,7-9]. The 
incidence of most serious postoperative morbid events, including paraplegia/paraparesis, myocardial infarction 
and respiratory insufficiency is approximately what is expected after open surgical treatment [7]. Strict anatomic 
inclusion criteria for endovascular treatment include aneurysms located distal to the origin of the left subclavian 
artery and proximal to the celiac trunk with a landing zone, equal or longer than 15 mm in length and aortic 
diameter not exceeding 40 mm [8]. 
Semba et al. successfully treated three patients with a mycotic thoracic aortic aneurysm, including one patient 
with a ruptured aneurysm, using endoluminal stent-graft placement. Responsible pathogens were Proteus 
mirabilis in one case and Clostridium septicum in another case. There were no perioperative death or life-
threatening complications during follow-up, periods of 4, 24 and 25 months, respectively. Lifelong antibiotic 
therapy was given [8]. Ishida et al. noticed a major endoleak after successful stent-graft placement in a patient 
with ruptured mycotic thoracic aneurysm caused by Staphylococcus aureus. The patient died despite emergent 
surgical treatment [9]. Berchtold et al. reported a case of successful endovascular treatment of an infected 
abdominal aortic aneurysm following septicaemia related to Salmonella. Antibiotics were given for 2 months 
and patient was doing well 2 years after procedure [10]. Stoica et al. reported a case of a patient with contained 
rupture of the descending aorta and positive culture for Salmonella enteritidis successfully treated by stent-graft. 
Antibiotics were given for 6 months. Patient was doing well 2 years after procedure [4].  
To the best of our knowledge this is the second case of endovascular stentgrafting reported as a treatment of 
thoracic aneurysm caused by Salmonella. Although the need for multiple stentgrafts increases the cost, overall 
cost-benefit ratio might still be in favour of endoluminal therapy, as hospital stay and postoperative care is 
reduced. This treatment may offer an alternative in patient with high operative risk. Long term postoperative 
antibiotherapy and regular follow-up are crucial. 
References 
[1] Hsu RB,  Tsay YG, Wang SS,  Chu SH  Management of aortic aneurysm infected with Salmonella. Br J Surg 2003;90:1080-4.  
[2] Wang JH, Liu YC, Yen MY, Wang JH, Chen YS, Wann SR, Cheng DL. Mycotic aneurysm due to non-typhy salmonella: report of 16 
cases. Clin Infect Dis 1996;23:743-7.  
[3] Meerkin D, Yinnon AM, Munter RG, Shemesh O, Hiller N, Abraham AS. Salmonella mycotic aneurysm of the aortic arch: case report 
and review. Clin Infect Dis 1995;21:523-8.  
[4] Stoica L, Chocron S, Falcoz PE, Etievent JP. Endovascular stent grafting for contained rupture of the descending thoracic aorta. Eur J 
Cardiothor Surg 2003;23:1068-70.  
[5] Lee MH, Chan P, Chiou HJ, Cheung WK. Diagnostic imaging of Salmonella-related mycotic aneurysm of aorta by CT. Clin Imaging 
1996;20:26-30.  
[6] Knosalla C, Weng Y, Yankah AC, Hofmeister J, Hetzer R. Using aortic allograft material to treat mycotic aneurysms of the thoracic 
aorta. Ann Thorac Surg 1996;61:1146-52.  
[7] Dake MD, Miller DC, Mitchell RS, Semba CP, Moore KA, Sakai T. The “first generation” of endovascular stent-grafts for patients with 
aneurysms of the descending thoracic aorta. J Thorac Cardiovasc Surg 1998;116:689-704.  
[8] Semba CP, Sakai T, Slonim SM, Razavi MK, Kee ST, Jorgensen MJ, Hagberg RC, Lee GK, Mitchell RS, Miller DC, Dake MD. Mycotic 
aneurysms of the thoracic aorta: repair with use of endovascular stentgrafts. J Vasc Interv Radiol 1998;9:33-40.  
[9] Ishida M, Kato N, Hirano T, Shimono T, Yasuda F, Tanaka K, Yada I, Takeda K. Limitations of endovascular treatment with stent-grafts 
foractive mycotic thoracic aortic aneurysm. Cardiovasc Intervent Radiol 2002;25:216-8.  
[10]  Berchtold  C,   Eibl  C,   Seelig  MH,   Jacob  P,   Schonleben  K. Endovascular treatment  and  complete regression  of an  infected 
abdominal aortic aneurysm. J Endovasc Ther 2002;9:543-8. 
